Pain Management · Opioid CombinationRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental Application for Percodan by Endo Operations

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:31:25 PM

Assessment confidence: 77% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Percodan signifies a potential shift in the competitive landscape of the opioid pain management market. This could impact market share dynamics and necessitate strategic adjustments from competitors. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 5 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of this approval on competitive dynamics and market share in the opioid pain relief category. The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 2 regulatory and 0 competitive items passed relevance filtering for Percodan.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance Endo Operations' position in the pain management market, particularly in the opioid segment..

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and market launch will be critical to assess compliance and market readiness.

Key Risks

Elevated medium regulatory exposure for Percodan could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Percodan could capture additional market share in the opioid segment, influencing revenue streams for Endo Operations and its competitors.
Upside for Percodan may improve if Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact of this approval on competitive dynamics and market share in the opioid pain relief category.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval process and any subsequent market launch timelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — PERCODAN (SUPPL)
FDAmedium relevance
Entity match (percodan)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Investigational New Drug (IND) Application
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — VANTAS (SUPPL)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase 1 Investigational New Drug (IND) Navigator
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — VEPPANU (ORIG)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Approves Tzield for Pediatric Stage 3 Type I Diabetes
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Warm intranasal saline irrigation reduces intraoperative blood loss during functional endoscopic sinus surgery: a propensity score-matched cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Percodan

Commercial impact

medium

If approved, Percodan could capture additional market share in the opioid segment, influencing revenue streams for Endo Operations and its competitors.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and market launch will be critical to assess compliance and market readiness.

What to watch

Monitor for further updates on the approval process and any subsequent market launch timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.